Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.

Eli Lilly on Thursday posted better-than-expected quarterly results, although sales of its popular weight-loss drug, Zepbound ...

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

Pharmaceutical company Eli Lilly announced ... once-a-day weight management pill. However, the pharmaceutical firm ran into some trouble two years into developing and testing the drug, finding ...

Novo Nordisk to sell Wegovy through telehealth firms to cash-paying US customers Novo Nordisk said on Tuesday it was working with telehealth firms Hims & Hers , Ro and LifeMD to sell Wegovy, as it ...

Shares in Eli Lilly rose sharply in pre-market trading ... adding that it is preparing to file the drug as a weight-loss treatment later this year and for diabetes in 2026. Chief executive David ...

Shares in Eli Lilly rose sharply in pre-market trading today after it reported phase 3 results for oral diabetes and weight-loss drug orforglipron. The importance of biosimilars only continues to ...

This double action makes it particularly effective at supporting weight loss when used alongside exercise ... may be covered by insurance. Eli Lilly, the manufacturer of Zepbound, made Zepbound ...

Therefore, for sensitive weight and weight loss drug related questions, Swiss Re suggested fostering anonymity over a “human touch” may help applicants feel more comfortable and enhance ...